General Information of Drug (ID: DM0N85H)

Drug Name
Vidarabine Drug Info
Synonyms
Araadenosine; Arabinosyladenine; Armes; RAB; Spongoadenosine; VIRDARABINE; Vidarabin; Vidarabina; Vidarabinum; Xylosyladenine; Adenine arabinoside; Adenine xyloside; Adenosine arabinose; Ara A; Arabinoside adenine; Arabinosyl adenine; Vidarabina [DCIT]; Vidarabine anhydrous; Vira ATM; Xylosyl A; A 9251; ARA-A NSC 247519; Alpha-Ara A; Ara-A; Arabinosyl-adenine; Arasena-A; Armes (TN); Beta-Ara A; Vidarabine (JAN); Vira-A; Adenosine-8-14C; Vira-A, Vidarabine; ADENOSINE, U.S.P.; (+)-Cyclaradine; 9-Arabinosyladenine
Indication
Disease Entry ICD 11 Status REF
Hepatosplenic T-cell lymphoma Approved [1]
Herpes simplex infection 1F00 Approved [1]
Herpes simplex virus infection 1F00 Approved [2]
Herpetic keratitis 1F00.10 Approved [1]
Immunodeficiency 4A00-4A85 Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Lung cancer 2C25.0 Approved [1]
MALT lymphoma Approved [1]
Myeloproliferative neoplasm 2A20 Approved [1]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma Approved [1]
Splenic marginal zone lymphoma Approved [1]
Testicular lymphoma Approved [1]
Colon cancer 2B90.Z Investigative [1]
Gastric cancer 2B72 Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
Therapeutic Class
Antiviral Agents
Cross-matching ID
PubChem CID
21704
ChEBI ID
CHEBI:45327
CAS Number
CAS 5536-17-4
TTD Drug ID
DM0N85H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [3]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [5]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [6]
YT-146 DM3YVKQ Hypertension BA00-BA04 Phase 2 [7]
AB928 DMDOXMN Metastatic colorectal cancer 2B91 Phase 1/2 [8]
KF-17837 DMQ6DLZ Parkinson disease 8A00.0 Phase 1 [9]
Xanthine DMFBOQ7 Apnea MD11.0 Phase 1 [10]
CVT-6883 DMY84TW Asthma CA23 Phase 1 [11]
PBF-1129 DMOPGXM Non-small-cell lung cancer 2C25.Y Phase 1 [8]
PF-1913539 DMXEU14 Alzheimer disease 8A20 Discontinued in Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [4]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [13]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [14]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [15]
Etidronic acid DM1XHYJ Bone Paget disease Approved [4]
Tiaprofenic acid DM23D7J Osteoarthritis FA00-FA05 Approved [4]
Bromperidol DM24XYQ Schizophrenia 6A20 Approved [4]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [16]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [17]
Quercetin DM3NC4M Obesity 5B81 Approved [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A2b receptor (ADORA2B) TTNE7KG AA2BR_HUMAN Modulator [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Gene/Protein Processing [4]

References

1 Vidarabine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4806).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
5 Clinical pipeline report, company report or official report of Klus Pharma
6 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
7 Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
10 Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
11 GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
12 Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
13 Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
14 Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
15 Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
16 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
17 Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
18 Stable cellular models of nuclear receptor PXR for high-throughput evaluation of small molecules. Toxicol In Vitro. 2018 Oct;52:222-234.